反応式
[CH3:1][S:2]([C:5]1[CH:31]=[CH:30][C:8]([O:9][CH2:10][C:11]2[CH:16]=[CH:15][C:14]([CH:17]3[CH2:22][CH2:21][N:20]([C:23](OC(C)(C)C)=O)[CH2:19][CH2:18]3)=[CH:13][N:12]=2)=[CH:7][CH:6]=1)(=[O:4])=[O:3].[CH2:32]([C:37]1[CH:38]=[N:39]C(Br)=[N:41][CH:42]=1)[CH2:33][CH2:34][CH2:35][CH3:36]>>[CH3:1][S:2]([C:5]1[CH:6]=[CH:7][C:8]([O:9][CH2:10][C:11]2[CH:16]=[CH:15][C:14]([CH:17]3[CH2:22][CH2:21][N:20]([C:23]4[N:41]=[CH:42][C:37]([CH2:32][CH2:33][CH2:34][CH2:35][CH3:36])=[CH:38][N:39]=4)[CH2:19][CH2:18]3)=[CH:13][N:12]=2)=[CH:30][CH:31]=1)(=[O:4])=[O:3]参加物
3
実験手順
The title compound was prepared from tert-butyl 4-[2-(4-methanesulfonylphenoxymethyl)pyridin-5-yl]piperidine-1-carboxylate (Example 1) (50 mg, 0.11 mmol) and 5-pentyl-2-bromopyrimidine (37 μL, 0.22 mmol) following a procedure analogous to that in Example 48 as a white crystal (35 mg, yield 64%).
出典と根拠
- ORDレコード
- ord-e8436764dc3747dababb18eb91fd24a0
- 出典データセット
- uspto-grants-2013_09
- 特許番号
- US08536176B2
関連ノート
読み込み中…